CTOs on the Move

Regenerative Processing Plant

www.regenerativeplant.org

 
Regenerative Processing Plant is a biotechnology company that manufactures various stem cell stimulants using patented D MAPPS technology. They offer a wide range of innovative high quality soft tissue and wound care products for tissue regeneration.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

UCS Healthcare

UCS Healthcare is a healthcare organization offering a variety of services from medical to treatment.

Monitored Therapeutics

Monitored Therapeutics Inc. is focused on solutions for the management of respiratory diseases like COPD, Asthma, Lung Transplant, and Cystic Fibrosis.

Covis Pharma

Covis Pharma is a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses. Our paramount concern is patient`s outcomes as we focus on improving the health of people with serious medical conditions. Covis Pharma is a standalone company with global commercial, business development, product supply chain, product development, quality and regulatory functions based in Zug, Switzerland.

Allergy Associates Research Center

Allergy Associates Research Center is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Respira Therapeutics

Respira Therapeutics, Inc., founded in 2010 with offices in Albuquerque, New Mexico, is a development stage inhaled pharmaceutical development company focused on commercializing its "best in class", high efficiency AOS-DPI, dry powder inhaler (DPI) drug delivery technology to deliver RT234, a proprietary inhaled formulation of an off patent oral drug via the lung to treatment of multiple orphan indications in the fields of pulmonary hypertension and other diseases. Investors in Respira include Cottonwood Technology Fund and Sun Mountain Capital and individual investors. To date Respira has performed extensive testing demonstrating its advanced AOS-DPI prototypes can deliver 2-3X more drug to the lung than commercially available DPI technologies. Respira is planning proof of concept clinical trials of an inhaled formulation of RT234 in pulmonary arterial hypertension patients in the near future.